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Mutant p53 Gain of Function in Two Mouse Models
of Li-Fraumeni Syndrome
with DNA, while structural mutations affect the global
structure of the p53 DBD. Both classes of mutant p53
proteins commonly accumulate to high levels in tumor
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cells and are defective for wild-type p53 function. Fur-and Tyler Jacks1,4,*
thermore, p53mutations have been linked to poor prog-1Center for Cancer Research
nosis in a variety of tumor types and have been shownMassachusetts Institute of Technology
to affect cellular responses to chemotherapeutics (ChoCambridge, Massachusetts 02139
et al., 1994; Peller, 1998). In addition to sporadic tumors,2Abramson Family Cancer Research Institute
p53 point mutations also occur in the germline of pa-University of Pennsylvania
tientswith Li-Fraumeni syndrome (LFS), a familial cancerPhiladelphia, Pennsylvania 19104
predisposition syndrome in which patients develop a3Department of Biomedical Sciences
broad spectrum of malignancies (Kleihues et al., 1997).Tufts University Veterinary School
Twoprominentmodels have beenproposed to explainNorth Grafton, Massachusetts 01536
the effects of p53missense mutation in cancer. The first4Howard Hughes Medical Institute
suggests that hetero-oligomerization between mutantChevy Chase, Maryland 20815
and wild-type p53 polypeptides results in dominant-
negative effects onwild-typep53 function.Considerable
biochemical and cell-based data support the ability ofSummary
different point mutant alleles to inhibit wild-type p53
function, but the effects can be complex. For example,The p53 tumor suppressor gene is commonly altered
some mutant alleles of p53 can inhibit the ability ofin human tumors, predominantly through missense
wild-type p53 to transactivate target genes involved inmutations that result in accumulation of mutant p53
apoptosis, but not those involved in cell cycle arrestprotein. These mutations may confer dominant-nega-
(Aurelio et al., 2000). Furthermore, the extent to whichtive or gain-of-function properties to p53. To ascertain
tumor-derived mutations in p53 confer dominant-nega-the physiological effects of p53 point mutation, the
tive effects under physiological conditions is unclear.structural mutant p53R172H and the contact mutant
The second model suggests that p53mutations activelyp53R270H (codons 175 and 273 in humans) were engi-
promote tumorigenesis independent of wild-type p53neered into the endogenous p53 locus in mice. p53R270H/
function. This “gain-of-function” model is supported byand p53R172H/ mice are models of Li-Fraumeni Syn-
several studies in which p53-null cell lines were trans-drome; they developed allele-specific tumor spectra
formed with mutant p53 constructs, resulting in in-distinct from p53/ mice. In addition, p53R270H/ and
creased tumorigenic potential (Dittmer et al., 1993;p53R172H/ mice developed novel tumors compared to
Hsiao et al., 1994; Shaulsky et al., 1991). Many studiesp53/ mice, including a variety of carcinomas and
have ascribed novel biochemical properties to mutantmore frequent endothelial tumors. Dominant effects
p53 that diverge from the function of wild-type p53,that varied by allele and function were observed in
including the ability to regulate distinct sets of targetprimary cells derived fromp53R270H/andp53R172H/mice.
genes and the ability to participate in novel protein-These results demonstrate that point mutant p53 al-
protein interactions (reviewed in Cadwell and Zambettileles expressed under physiological control have en-
[2001]). Little is known about the relevance of thesehanced oncogenic potential beyond the simple loss of
observations in vivo.p53 function.
Substantial efforts have been made to model LFS in
mice. We and others engineered mice lacking expres-
Introduction sion of the p53 protein. p53 knockout mice are highly
cancer prone; however, in contrast to LFS patients, the
The p53 tumor suppressor gene encodes a transcription tumor spectrumof p53 knockoutmice is fairly restricted;
factor that responds to cellular stresses by regulating both heterozygous and homozygous p53 knockoutmice
genes involved in cell cycle arrest, apoptosis, and other develop primarily sarcomas and lymphomas. Carcino-
pathways (reviewed in Levine [1997]). The p53 protein mas in these mice are rare, particularly in p53-null mice
contains a core sequence-specific DNA binding domain (Donehower et al., 1992; Jacks et al., 1994; Purdie et
(DBD) that directly binds to sequences in target gene al., 1994). A number of groups have produced transgenic
promoters. Missense mutations in the p53 DBD occur strains that overexpress mutant p53 from exogenous
in a large fraction of human tumors and have been found promoters (Harvey et al., 1995; Lavigueur et al., 1989;
in over 50 different types of cancer. Large deletions, Li et al., 1998; Wang et al., 1998). In each case, mutant
though common in other tumor suppressor genes, occur p53 transgene expression resulted in accelerated spon-
rarely in p53 (Olivier et al., 2002). Tumor-derived point taneous or carcinogen-induced tumor development,
mutations in p53 fall into two general classes: contact supporting a dominant effect for mutant p53. For exam-
mutations affect p53 residues that make direct contact ple, a p53135V transgene conferred accelerated tumori-
genesis and an altered tumor spectrum on p53/ and
p53/ mice (Harvey et al., 1995). Similarly, Liu et al.*Correspondence: tjacks@mit.edu
5These authors contributed equally to this work. (2000) found an increased incidence of carcinomas and
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metastatic osteosarcomas, compared to p53/ mice, p53R270H/ and p53R172H/ samples, while only the wild-
type allele was expressed in p53LSL·R270H/ and p53LSL·R172H/in mice heterozygous for an endogenous mutant allele
of p53 (p53R172Hg); however, analysis of these mice was samples (Figure 1D and data not shown). In addition,
cDNAs derived from p53R270H/ and p53R172H/ primaryconfounded by the presence of an extraneous splice
acceptor mutation. mouse embryo fibroblasts (MEFs; see below) were se-
quenced, confirming the presence of only the desiredIn order to accurately model LFS in mice and to in-
vestigate the potential for dominant-negative or gain- mutations (data not shown). Quantitative real-time PCR
analysis for p53 confirmed that the point mutant allelesof-function effects by mutant p53, we constructed and
characterized twomouse strainswith endogenous point are expressed at levels comparable to wild-type p53 in
MEFs (Figure 1E).mutations of p53. These strains harbor contact or struc-
tural mutations that together comprise two of the three Mutant p53 protein often accumulates to high levels
in human tumors, and some mutant proteins adopt anmost commonly mutated p53 codons in human cancer.
These mice closely mimic humans with LFS both geno- altered conformation. In particular, structural mutants
assume a partially denatured conformation that resultstypically and phenotypically. Moreover, data from these
mice provide compelling evidence for gain-of-function in the exposure of novel epitopes recognized bymutant-
specific -p53 antibodies. In contrast, contact mutantseffects by mutant p53.
have been described either as “flexible” (reactive to both
wild-type- and mutant-specific antibodies) or as fullyResults
wild-type in conformation (Webley et al., 2000; Yewdell
et al., 1986). In order to examine the biochemical prop-Generation of Germline Point Mutant p53 Mice
erties of mutant p53 proteins, mice that express onlyTwo conditional point mutant p53 alleles were engi-
point mutant p53 were generated by crossing p53M/neered into the endogenous murine p53 locus. They
mice to p53/ mice (Jacks et al., 1994) to generateencode the contact mutant p53R270H and the structural
p53R270H/ and p53R172H/ mice (collectively referred to asmutant p53R172H, both of which are commonly found in
p53M/ mice). These mice appeared grossly similar tospontaneous human tumors and in the germline of LFS
p53/ mice at birth and throughout development (seekindreds. (Murine p53 codons 270 and 172 correspond
below). They were born in expected Mendelian ratiosto human p53 codons 273 and 175.) In order to enable
except for a slight decrease in the number of p53M/tissue- or stage-specific expressionofmutantp53 under
females, a phenotype that is also observed in p53/physiological conditions, conditional mutant alleles of
animals due to female-specific exencephaly (Sah et al.,p53 were generated by introducing the LoxP-flanked
1995). Figure 1F shows aWestern blot for p53 performedtranscriptional STOP cassette into intron 1 of the p53
on MEF whole-cell lysates confirming that mutant p53gene. This Lox-STOP-Lox (LSL) cassette was used by
accumulated to high levels in these cells. In addition,our group previously to create a conditional oncogenic
these experiments also revealed that the contactmutantallele ofK-ras; it efficiently blocks expression of targeted
p53R270H accumulated to higher levels in p53M/ MEFsloci prior to removal of the STOP element by Cre recom-
than the structuralmutant p53R172H. This effectwas repro-binase (Tuveson et al., 2004). Site-directedmutagenesis
duced using three different antibodies against p53 (datawas used to introduce an arg→his mutation at either
not shown). As shown in Figure 1G, the structural mutantcodon 270 or codon 172, resulting in the conditional
p53R172H was preferentially immunoprecipitated by themutant alleles p53LSL•R270H and p53LSL•R172H (Figure 1A).
mutant-specific antibody PAb 240while the contactmu-These alleles were verified by sequencing the entire p53
tant p53R270H was preferentially immunoprecipitated byopen reading frame and all intron/exon boundries in
the wild-type-specific antibody PAb 1620.the targeting vectors (data not shown). Both alleles were
targeted into J1 embryonic stem cells, and germline
transmission was achieved in multiple clones. Presence p53M/ Mice Develop Distinct Tumor Spectra
In order to evaluate whether the p53M/ mouse strainsof the STOP cassette in intron 1 of p53 in these mice
was determined by PCR (Figure 1B), and the presence are improved models of LFS and to compare the effects
of p53 point mutation to p53-null mutation, a cohort ofof each mutation was reconfirmed by sequencing (data
not shown). 37 p53R270H/, 41 p53R172H/, and 37 p53/ mice were
aged and monitored for the onset of malignancy. AsIn order to study the effects of endogenous expres-
sion of the mutant p53 alleles in all tissues of the mouse, shown in Figure 2A, the life spans of p53R270H/, p53R172H/,
and p53/ mice were similar with mean survival timesp53LSL•R270H/ and p53LSL•R172H/micewere crossed to prot-
amine-Cre transgenicmice, which expressCre recombi- of 15.8, 15.2, and 15.4 months, respectively (Kaplan-
Meyer log-rank test). Each mouse was subjected to anase in haploid sperm (O’Gorman et al., 1997). Resulting
p53LSL·R270H/; PrmCre/ and p53LSL·R172H/; PrmCre/ complete necropsy, and histopathological analysis of
all tissues regardless of whether tumors were apparent.male mice were then crossed to wild-type 129S4/SvJae
females to generate p53R270H/ and p53R172H/ mice (col- The pathology of each mouse in this study is available
in the Supplemental Data at http://www.cell.com/cgi/lectively referred to as “p53M/” mice). Tail DNA samples
from offspring were analyzed by PCR (Figure 1C). content/full/119/6/847/DC1/.
The p53M/mice demonstrated significant differencesSuccessful generation of conditional and germline
point mutant p53 mice was verified by several means. in their tumor spectra, both compared to the p53/
mice as well as to each other (Figure 2B). The p53R270H/p53 cDNAs were derived from p53M/ and p53LSL·M/
mousebrains andsequenced. As expected, bothmutant mice had an increased incidence of carcinomas com-
pared to p53/ mice (2, p  0.017). In particular, 7/36and wild-type alleles were found to be expressed in
Point-Mutant p53 Knockin Mice
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Figure 1. Generation, Targeting, and Verification of Conditional Point Mutant p53 Alleles
(A) The endogenous p53 locus is depicted at top, followed by the p53 LSL·R270H and p53 LSL·R172H targeting vectors. Asterisks indicate the sights
of point mutations. Targeted mutant p53 alleles are shown at bottom. Restriction sites are indicated: R, EcoRI; B, BamHI; H, HinDIII; X, Xho;
Nd; NdeI, Xb, Xba; S, Sal.
(B) PCR amplification of conditional mutant alleles results in a 270 bp mutant product and a 166 bp control product.
(C) PCR primers flanking the LSL cassette yield a 290 bp wild-type band and a 330 bp mutant p53 band.
(D) Sequence traces from p53 LSL·R270H/ (bottom) and p53R270H/ (top) mouse brain cDNAs. N indicates expression of both the wild-type allele
(C) and the mutant allele (T).
(E) qRT-PCR analysis of p53 in WT, p53R172H/ and p53R270H/ MEFs. Histograms depict log2 induction relative to background in p53/ MEFs
and are the average of three different MEF lines, each assayed in triplicate. Error bars indicate standard error.
(F) Western blot analysis of MEF whole-cell lysates shows accumulation of mutant p53 proteins.
(G) Conformation of mutant p53 proteins was determined by immunoprecipitation of p53 proteins from 1000 g of MEF whole-cell lysates
with 10 l of either p53 Ab5 (ORP), p53 Ab3 (ORP), or FL-393 (Santa Cruz), followed by Western blotting with p53 Ab7 (ORP).
p53R270H/ mice developed lung adenocarcinomas, in- (5/7), desmoplasia (4/7), andmetastasis (2/7). Other car-
cinomas found inp53R270H/mice included five squamouscluding several with malignant features commonly seen
in human lung adenocarcinoma such as nuclear atypia cell carcinomas, two hepatocellular carcinomas, a tran-
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Figure 2. Mice Heterozygous for Mutant p53
Develop Novel Tumors
(A) Kaplan-Meyer plot demonstrates no dif-
ference in survival time between p53/,
p53R270H/, and p53R172H/ mice.
(B) Distinct tumor spectra in p53M/mice. His-
tograms show the fraction of p53/ (blue),
p53R270H/ (red), and p53R172H/ (green) mice
that developed the indicated tumors. See
Supplemental Figure S1 on the Cell website
for additional data.
(C) PCR analysis was performed on matched
tumor (T) and somatic (S) DNA samples to
look for LOH. At left is a dilution series of
p53M/M and p53/ DNA for reference.
sitional cell carcinoma of the kidney, and an intestinal nodes and spread through the abdominal cavity, some-
times invading adjacent organs such as the kidneyscarcinoma (Supplemental Figures S2A–S2C on the Cell
website). Many of these tumorswere invasive or showed and intestines (Supplemental Figure S3B on the Cell
website). Overall,p53R270H/mice had an increased tumorevidence of distal metastases (Supplemental Figures
S2D and S2E on the Cell website). Immunohistochemis- burden compared to p53/mice; 44%of p53R270H/mice
had developed multiple tumors at the time of necropsytry (IHC) was performed on some tumors to further sup-
port their epithelial origin (Supplemental Table S1 and compared to 19% of p53/ mice (2, p  0.03).
In contrast to the frequent carcinomas in p53R270H/Supplemental Figure S3A on the Cell website). In con-
trast to the p53R270H/mice, only four low-grade carcino- mice, the most frequent tumors in the p53R172H/ mice
were osteosarcomas. Roughly twice as many p53R172H/mas were found in 37 p53/ mice, similar to previous
reports (Donehower et al., 1992; Jacks et al., 1994). The mice developed osteosarcomas as did p53/ and
p53R270H/ mice (2, p  0.043 for p53/ mice, p  0.039single lung carcinoma observed in a p53/ mouse was
well differentiated and lacked severely dysplastic nuclei for p53R270H/ mice). These tumors developed primarily
in trabecular regions of vertebrae or longbones. Diffuseor stromal deposition. Premalignant epithelial lesions
such as adenomas and papillomaswere alsomore com- osteopetrosis was commonly observed concurrent with
the osteosarcomas. In addition, the p53R172H/ osteosar-mon in the p53R270H/ mice than in the p53/ mice (Sup-
plemental Figure S1 on the Cell website). comas metastasized more frequently than those in the
p53/ or p53R270H/ mice, generally to the liver, lung, orIn addition to carcinomas, p53R270H/mice also had an
increased incidence of B cell lymphomas. 5/36 p53R270H/ spleen (Supplemental Figures S2E and S2F on the Cell
website). Only four osteosarcomas in p53R172H/mice didmice developed B cell lineage tumors (2, p  0.031;
Supplemental Figures S3B and S3C on theCellwebsite). not metastasize, including two early lesions found in
mice that died from other causes. The p53R172H/ miceThey generally arose in the spleen or mesenteric lymph
Point-Mutant p53 Knockin Mice
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also developed carcinomas slightly more frequently
than p53/ mice (2, p  0.38); however, they did not
display the high frequency of lung adenocarcinomas
noted in p53R270H/ mice.
Tumors that develop in humans with hereditary p53
mutations frequently lose the remaining wild-type p53
allele. It was therefore of interest to determine the status
of the wild-type p53 allele in tumors from p53M/ mice.
The mutant p53 reaction described earlier (Figure 1C)
was modified to be quantitative by terminating the reac-
tion after 29 cycles rather than 35. The sensitivity of this
assay was confirmed by running a dilution series of
p53/ and p53M/M samples (Figure 2C). PCR analysis of
DNA derived from p53M/ tumors revealed evidence
of loss of heterozygosity (LOH) in 10/19 tumors analyzed
(4/10 p53R270H/ and 6/9 p53R172H/), further validating
these mice as models for LFS.
Dominant Effects of Mutant p53 in Primary Cells
There are several potential explanations for the differ-
ences in tumor spectra between the p53M/ mice and
p53/mice.Mutantp53may act in a dominant-negative
manner to interfere with the function of the wild-type
p53 allele. Alternatively, the mutant p53 alleles may con-
tribute novel protumorigenic functions. These twomecha-
nisms are not mutually exclusive. In order to assess the
dominant effects of endogenous mutant p53, several
well-established assays for p53-dependent functions
were performed on p53M/ MEFs and thymocytes. For
Figure 3. Dominant Effects by Mutant p53 in Primary Cellsexample, p53 can act to restrain cell proliferation, as
(A) S phase fraction in p53M/ MEFs. Cell cycle analysis was per-p53/MEFscyclemore quickly thanwild-typeorp53/
formed on exponentially growing MEFs. Histograms show the per-MEFs. Therefore, we measured cell proliferation in
cent of untreated cells (solid bars) or doxorubicin-treated cellsp53M/MEFs by analyzing the fraction of cells in S phase
(hashed bars—0.2 g/ml, 12 hr) in S phase as measured by FACSvia FACSanalysis of bromodeoxyuridine (BrdU) andpro- analysis of bromo-deoxyuridine and propidium iodide incorporation.
pidium iodide (PI) incorporation. As expected, a large Histograms show the average values of four independently derived
fraction of p53/ MEFs were in S phase during expo- MEF lines for each genotype. Error bars show standard deviation.
See Supplemental Figure S3A on theCellwebsite for additional data.nential growth compared to wild-type or p53/ MEFs.
(B) Apoptosis in thymocytes from p53M/ mice. Thymocytes wereInterestingly, both the p53R270H/ and p53R172H/MEFs had
isolated from 6- to 9-week-old mice and treated with 5Gy of  radi-a larger S phase fraction than did p53/ MEFs, with
ation. Apoptosis was measured by FACS analysis of Annexin-Vthe p53R172H/ MEFs appearing comparable to p53/ expression and propidium iodide exclusion. Graph depicts the per-
MEFs in this assay (Figure 3A, solid bars and Supple- centage of viable cells (Annexin-V-negative, propidium iodide-nega-
mental Figure S4A on the Cell website). Evidence of an tive) at 12 and 24 hr post treatment, normalized to untreated con-
trols. The average values from at least three mice per genotypeelevated proliferation rate in p53R172H/ MEFs was also
are shown.apparent when they were submitted to the classi-
cal 3T3 passaging protocol (Todaro and Green, 1963).
p53R172H/MEFs grew as rapidly as p53/ MEFs for four
passages before entering replicative senescence. Im- p53M/MEFs. As shown in Figure 4A, the amount of total
p53 in untreated p53M/ MEFs was elevated comparedmortalized clones quickly escaped senescence and
PCR analysis demonstrated loss of the wild-type p53 to p53/ or p53/ MEFs and increased further upon
treatment with doxorubicin. p21 levels, however, wereallele in these clones (Supplemental Figure S4B on the
Cell website and data not shown). p53 is also required comparable to those found in p53/ MEFs, suggesting
thatmixedmutant andwild-type p53 tetramers are com-for G1 arrest in MEFs after DNA damage (Kastan et al.,
1992). Surprisingly, the DNA damage-induced G1 arrest petent to transactivate at least some target genes. An
IP-Western forMDM2 supports this notion and also sug-response was intact in p53M/ MEFs: after treatment
with the DNAdamaging agent doxorubicin, p53M/MEFs gests that the accumulation of high levels of mutant p53
in these cells is not due to a loss of MDM2 transactiva-arrested in the G1 phase to a similar extent as wild-type
cells (Figure 3A). Thus, physiological expression of point tion by mutant p53.
Finally, in order to analyze the ability of p53M/ cells tomutant p53 in MEFs appears to dominantly interfere
with cellular functions related to basal proliferation but undergo p53-dependent apoptosis, primary thymocytes
were isolated from 6- to 8-week-oldmice. The apoptoticdoes not affect DNA damage-induced G1 arrest.
AsDNAdamage-inducedG1 arrest inMEFs is primarily response of p53M/ thymocytes to 5Gy of  radiation
was assayedby FACSanalysis for Annexin-V expressiondependent on the ability of p53 to transactivate the cell
cycle inhibitor p21, this pathway was investigated in and propidium iodide exclusion. The relative fraction of
Cell
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Figure 4. p53 Target Gene Expression in Mu-
tant p53 Cells
(A) Immunoblots for p53, φ-ser15-p53, and
p21 on MEF whole-cell lysates are shown.
MDM2 immunoprecipitates from the same
extracts are also shown.
(B) Immunoblots for p53, φ-ser15-p53, and
p21 on MEF whole-cell lysates are shown.
MDM2 immunoprecipitates from the same
extracts are also shown.
viable cells after doxorubicin treatment is shown in Fig- of age, with a mean survival time of 4.4, 4.5, and 4.6
months for the p53/, p53R270H/ and p53R172H/ mice,ure 3B. As expected, p53/ thymocytes were com-
pletely resistant to radiation-induced apoptosis through respectively. There was no significant difference in the
survival of p53 mutant mice compared to p53-null mice24 hr, whereas only 20% of wild-type thymocytes sur-
vived to this time point. Both p53R270H/ and p53R172H/ (Kaplan-Meyer log rank test, Figure 5A).
In support of the mutant p53 gain-of-function hypoth-thymocytes were partially resistant to -induced apo-
ptosis. The p53M/ thymocytes were more resistant to esis, two significant differences were observed in the
tumor spectra of the p53M/ mice compared to p53/apoptosis than p53/ cells, consistent with a dominant
effect by point mutant proteins on apoptosis. These mice (Figure 5B). In previous studies, p53/ mice pri-
marily developed lymphomas and sarcomas and rarelyresults are similar to previous experiments on point mu-
tant p53 thymocytes generated by Rag2/ blastocyst developed carcinomas. Likewise, none of the p53/
mice in this study developed carcinomas. In contrast,complementation (de Vries et al., 2002).
carcinomas were observed in 18% of the p53R270H/mice
and 16% of p53R172H/ mice (2, p  0.008 for p53R270H/p53 Gain of Function: Mutant p53 Predisposes
Mice to Epithelial and Endothelial Tumors and p  0.015 for p53R172H/). Carcinomas found in the
point mutant p53 mice arose in a variety of differentTo directly evaluate the p53 gain-of-function hypothesis
in vivo, spontaneous tumor development in mice ex- tissues including lung, small intestine, colon, breast,
skin, liver, and pancreas. These tumors developed inpressing only mutant p53 was compared to that in mice
lacking p53. If the point mutant p53 alleles possess mice ranging from 1.5 to 6.9 months of age and, in one
case, two different primary carcinomas were observedinherent oncogenic functions, p53M/ mice could have
a more pronounced tumor phenotype than p53-null in the same mouse. Most of the carcinomas showed
evidence of invasion, metastasis, or other features com-mice. Forty-one p53/, forty p53R270H/, and forty-five
p53R172H/ mice were generated as described above. All monly seen in advanced human carcinomas such as
desmoplasia and stromal invasion (Figures 6A–6E). Inof the mice required euthanasia or died by 8.5 months
Point-Mutant p53 Knockin Mice
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Figure 5. Point Mutant p53 Mice Develop
Novel Tumors Compared to p53 Knockout
Mice
(A) Kaplan-Meyer plot demonstrates no dif-
ference in survival time of p53/, p53R270H/,
and p53R172H/ mice.
(B) Histograms show the fraction of p53/
(blue), p53R270H/ (red), and p53R172H/ (green)
mice that developed the indicated tumors.
most instances, the epithelial origin of these tumors was oped multiple tumors, compared to 43% of p53R270H/
mice (2, p  0.31) and 57% of p53R172H/ mice (2, p readily apparent through histopathology; however IHC
was also used to support these diagnoses (Supplemen- 0.02).
tal Figures S3E–S3F and Supplemental Table S1 on the
Cell website). Mutant p53 Accumulation in Tumors
Tumors cells from LFS patients often show nuclear ac-In addition to epithelial tumors, the point mutant p53
mice also demonstrated an increased incidence of hem- cumulation of mutant p53 protein. In order to determine
whether tumors from p53M/ mice were similar in thisangiosarcomas (Figures 5B and 6F). The p53R172H/mice,
in particular, showed a significant increase to 62% inci- respect, IHC for p53 was performed on tumors from
the aging studies. (Supplemental Figures S6A–S6C anddence (27/45), compared to 32% (13/41) in the p53/
mice (2, p  0.005). These tumors were highly aggres- Supplemental Table S2 on the Cell website). Interest-
ingly, 12/16 carcinomas from p53M/mice exhibited sub-sive, demonstrated marked nuclear atypia, and stained
positively for the endothelial tumor marker Fli-1 (data stantial nuclear accumulation of p53 protein. Three of
the four tumors that did not accumulate p53 were low-not shown).
Similar to previous studies, 66% of the p53/ mice grade lung adenocarcinomas. More advanced lung ade-
nocarcinomas stained positively for p53 accumulationin this study developed hematological malignancies, pri-
marily T cell lymphomas. A slight decrease in the inci- in patches that correlated withmoremalignant histology
(Supplemental Figure S6C on the Cell website). In addi-dence of hematological malignancies was observed in
p53M/mice (55%ofp53R270H/miceand 50%ofp53R172H/ tion, 11/13 osteosarcomas in p53M/ mice were found
to accumulate p53 to high levels in at least a subsetmice), although there was no shift in the survival time
of p53M/ mice with lymphomas. The other tumors ob- of cells.
Several carcinomas that stained positively for p53alsoserved in p53M/ mice were found at frequencies similar
to that of p53/mice.Overall, 32%of p53/mice devel- exhibited stromal desmoplasia. In each case, the stro-
Cell
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Figure 6. Histopathology of Point Mutant p53 Tumors Stained with Hematoxylin and Eosin
(A) A moderately differentiated p53R172H/ colon adenocarcinoma with a high mitotic index, severe nuclear dysplasia (arrows), desmoplasia,
and stromal invasion (400X).
(B) A p53R172H/ squamous cell carcinoma with well-differentiated cells forming a keratin pearl (K) and poorly differentiated cells alone or in
small clusters (arrows) surrounded by tumor stroma (400X).
(C) A highly pleomorphic hepatocellular carcinoma (T) from a p53R270H/ mouse. Note the bizarre, enlarged nuclei found within the tumor
compared to the nuclei of adjacent normal hepatocytes (N) (400X).
(D) Intralymphatic metastasis (M) from a p53R172H/ colon adenocarcinoma. Arrow indicates the lymphendothelium (400X).
(E) Wright-Giemsa-stained peripheral blood smear from a p53R172H/mouse with a colon adenocarcinoma. Circulating tumor cells are indicated
(T), including an actively dividing polyploid cell with a roughly 8N complement of chromosomes. Nearby are a normal neutrophil (N) and a
cluster of platelets (P) (1000X).
(F) A p53R172H/ hemangiosarcoma (400X).
mal cells did not express high levels of p53 (Supplemen- that LOH in a tumor generally correlated with the ac-
cumulation of mutant p53 protein. However, theretal Figures S6A and S6B). Likewise, normal tissues from
p53M/mice did not showevidence of p53 accumulation. were several exceptions: tumors were found that had
undergone LOH but did not accumulatemutant p53 and,These data might indicate that residual p53 function in
p53M/ mice is sufficient to restrain p53 accumulation in conversely, that accumulated mutant p53 but retained
heterozygosity. Furthermore, if mutant p53 protein ac-normal but not neoplastic cells. Alternatively, the tumor
cells that accumulated p53 might have lost their wild- cumulation is dependent on a loss of wild-type p53
function, it would follow that mutant p53 would accumu-type p53 allele. Indeed, in determining whether LOH had
occurred in p53M/ tumors (see above), it was observed late to high levels in the normal tissues of p53M/ mice,
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which lack any wild-type p53 function. To test this di- expression of mutant p53, a cell line, Os1, was derived
from an osteosarcoma metastasis that arose in arectly, IHC for p53 was performed on tumors and normal
tissues from p53M/ mice. As shown in Supplemental p53R172H/ mouse. Analysis of DNA from Os1 cells indi-
cated that they had lost their wild-type p53 allele (dataTable S2 on the Cell website, p53 was readily detected
in the majority of, but not all, p53M/ tumors. However, not shown). Os1 cells were infected with pSicoP-p53,
selected in puromycin, and then superinfected with ei-in no case was p53 accumulation observed in normal
tissues from these mice. Furthermore, as shown in Sup- ther a Cre-expressing adenovirus (AdCre) or a control
adenovirus (AdEmpty). The percentage of cells infectedplemental Figures S6D–S6F on the Cell website, mutant
p53 does accumulate in normal tissues of p53M/ mice by AdCre was greater than 90%, as assessed by the
renewed susceptibility of the cells to puromycin (theafter  irradiation, but only in the same cells and tissues
observed to accumulate p53 in wild-type animals. Thus, puromycin resistance cassette is lost upon activation
of shRNA expression by Cre). To control for potentialtumor-associated increases in p53 staining cannot be
ascribed solely to the p53genotype of the cell, but rather side effects of expressing Cre recombinase, parental
Os1 cells were also treated with AdCre (Figure 7A). Thewould appear to reflect a secondary event that causes
mutant p53 stabilization. Interestingly, thymic lympho- infected cells were expanded, and protein was collected
fromcells in the presenceor absence of theDNAdamag-mas, which occur frequently in p53/, as well as p53M/
mice, consistently showed a lack of p53 accumulation, ing agent (cisplatin). As seen in Figure 7B, p53 shRNA
expression resulted in substantial knockdown of mutantperhaps indicating that the initiation of this tumor re-
quires only the loss of p53 function. p53, both before and after treatment with cisplatin.
In the course of expanding the cells, it was noticed
that the p53 shRNA-expressing cells grew more slowlyLoss of Wild-Type Function in p53M/ Primary Cells
than the control cells. To quantify this effect, a prolifera-Point mutant p53 alleles have alternatively been re-
tion assay was performed on p53 shRNA-expressingported to be completely or partially defective in trans-
and control Os1 cells. As seen in Figure 7C, Os1 cellsactivation (Forrester et al., 1995). In order to determine
proliferate more slowly after knockdown of mutant p53.whether the p53R270H and p53R172H mutants had lost wild-
As this experiment took place several passages subse-type p53 activity, the cellular assays described above
quent to the initial adenoviral infections, the experimentswere carried out on p53M/ and p53/ MEFs. No differ-
were repeated just 48 hr after infection with AdCre orence was seen between the point mutant MEFs and
AdEmpty. As seen in Figure 7D, the inhibition of prolifer-p53/MEFs in basal S phase fraction or in doxorubicin-
ation was even more dramatic immediately after infec-induced cell cycle arrest (Supplemental Figure S5A on
tion. This effect was visualized by diluting the cells 1:500the Cell website). p53M/ MEFs were also found to be
with wild-type MEFs and allowing them to grow to highimmortal by 3T3 assay, but they were unable to form
density (Figure 7E).foci at high density or to form colonies in soft agar,
It was previously reported that mutant p53 can bindsimilar to p53/MEFs (Supplemental Figure S5Bon the
to and inhibit the function of family-member proteinsCell website and data not shown). Likewise, there was
p63 and p73. In order to determine whether this occursno difference between p53/, p53R270H/, and p53R172H/
in Os1 cells, p73 immunoprecipitates were probed withMEFs in their abilities to induce colony formation at low
an antibody against p53. As shown in Figure 7F, mutantdensity or their abilities to proliferate in low serum (data
p53 was coimmunoprecipitated with p73, but not by anot shown). Finally, mutant p53 alleles were defective
mouse antibody specific for an unrelated protein. Similarin inducing apoptosis in primary thymocytes after  irra-
results were seen with an antibody against p63 and adiation, similar to p53/ thymocytes (data not shown).
second antibody against p73 (data not shown). Further-In order to assess the ability of mutant p53 to transacti-
more, qPCR experiments demonstrated an increase invate target genes, Western blotting for p53, p53φ-ser15, p21,
p63 and p73 target gene expression following knock-and MDM2 was performed on protein extracts from
down of mutant p53 (data not shown). These resultsp53M/ MEFs. Although mutant p53 accumulated and
support the inhibition of p63 and p73 by protein-proteinwas phosphorylated in response to doxorubicin treat-
interaction as a potential mechanism for the observedment, p21 and MDM2 were not induced in mutant p53
gain of function by mutant p53.MEFs (Figure 4B).
Mutant p53 Gain of Function Discussion
in Tumor-Derived Cells
Previous work has demonstrated that overexpression p53 was described 25 years ago as a cellular protein
bound by the SV40 large T antigen and as a tumor anti-ofmutant p53 protein inp53-null cells results in aggrava-
tion of the tumorigenic phenotype of those cells. The gen expressed in carcinogen-induced mouse tumors
(DeLeo et al., 1979; Lane and Crawford, 1979; Linzerreverse experiment, however, has not been performed
on contact or structural mutant p53-bearing cells. We and Levine, 1979). p53 was originally considered to be
an oncogene due to its ability to cooperate in the trans-therefore utilized a conditional lentiviral shRNA expres-
sion construct, pSico-p53 (Ventura et al., 2004), to knock formation of cells (Eliyahu et al., 1984; Parada et al.,
1984) and its overexpression in tumors and transformeddown mutant p53 expression in an endogenous setting.
To allow selection of cells bearing the conditional cells. However, a series of observations changed the
perception of p53 function in tumorigenesis, suggestingshRNA, a puromycin resistance cassette was substituted
for the GFP cassette of pSico-p53, to give pSicoP-p53. that it acted instead as a tumor suppressor gene. First,
p53 cDNAs that hadbeen used in oncogene cooperationIn an effort to find a cellular system sensitive to the
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Figure 7. Mutant p53 Gain of Function in Tumor-Derived Cells
(A) Os1 cells were infected with pSicoP-p53 and AdCre to knock down endogenous mutant p53. Control cells were infected with AdCre alone
or pSicoP-p53  AdEmpty.
(B) Western blot for p53 in Os1  pSicoP-p53 after infection with AdCre or AdEmpty demonstrates a strong shRNA-mediated knockdown of
mutant p53. The membrane was also probed with an antibody against vinculin as a loading control.
(C and D) Os1 cells proliferate more slowly after mutant p53 knockdown. 3 	 104 cells/well were plated in 12 well dishes, and cells from two
wells were counted daily. Experiments were initiated either three passages after adenoviral infection (C) or immediately following infection (D).
(E) Os1 cells proliferate to higher density prior to mutant p53 knockdown. Immediately following adenoviral infection, 2 	 104 Os1 cells were
diluted into 1 	 106 wild-type MEFs and plated in 10 cm dishes. After 1 week, cells plates were stained with Wright-Giemsa. Darker staining
in plates without mutant p53 KD reflect the ability of Os1 cells to rapidly grow to high density rather than their ability to form classic foci.
(F) Mutant p53 is coimmunoprecipitated by p73 Ab2 (ORP), but not by a control antibody.
Immunoblot was performed using p53 Ab7.
assays were found to be mutant, and wild-type p53 mutations in p53. First, p53M/ mice are models of Li-
Fraumeni syndrome that better recapitulate the humancDNAs were shown to inhibit cellular transformation
(Finlay et al., 1989; Hinds et al., 1989). Second, p53 was familial syndrome than do p53/ mice. Moreover,
p53R270H/ mice develop distinct tumor spectra fromdetermined to be mutated frequently and at numerous
codons in a wide range of human tumors and was seen p53R172H/mice, indicating that different p53 point muta-
tions confer subtly different functions. Specific func-to undergo loss of heterozygosity with high frequency
(Baker et al., 1990; Hollstein et al., 1991). Finally, loss-of- tional assays on primary cells derived from p53M/ mice
also support this conclusion. p53M/mice develop tumorfunction mutations in p53 in the mouse led to profound
cancer predispositions. In this light, the tumor-associ- spectra distinct from p53-null mice, and tumor cells de-
rived from mutant p53mice are sensitive to the shRNA-ated point mutations in p53 were generally viewed to
be acting in a dominant-negative manner to inhibit wild- mediated knockdown of mutant p53, strongly support-
ing a gain-of-function effect by mutant p53.type p53.
While the tumor-suppressive functions of wild-type
p53 are not in question, there have been persistent re- p53M/ Mice Are Models of Li-Fraumeni Syndrome
Of the 20 or so tumor suppressor genes associated withports that point mutant p53 proteins can affect transfor-
mation independent of wild-type p53. These studies human familial cancer syndromes, p53 is unusual in that
it is commonly altered throughmissensemutation ratherhave led to the suggestion that point mutant p53 has
gain-of-function oncogenic properties. However, because than deletion and because mutant p53 proteins are
upregulated in tumors. A few LFS kindreds have alter-these experiments have involved ectopic overexpres-
sion of the mutant p53 allele, they have been interpreted ations akin to null alleles of p53. An analysis of seven
such families concluded that these patients developedwith caution. Here we describe a definitive test for the
existence of oncogenic functions of point mutant p53. fewer cancers overall and at an older age than LFS
patients with point mutations in the p53 DBD (Birch etSeveral important conclusions can be drawn from the
analysis of mice with knockin alleles of tumor-derived al., 1998). However, a separate study foundnodifference
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between point mutant and truncation mutant LFS kin- type p53 or interference with other factors involved in
radiation-induced apoptosis.dreds (Hwang et al., 2003). The small number of these
patients combined with their diverse genetic back- Similarly, the novel tumor phenotypes of p53M/ mice
could be due to either dominant-negative effects, domi-grounds complicates this analysis. In contrast, our work
shows a clear difference in tumor spectra in p53M/mice nant gain-of-function effects or a combination of both.
For example, one interpretation of the development ofcompared to p53/ mice. Although there was no
change in survival time of mice with different genotypes, lung carcinomas in p53R270H/mice is that this allele con-
fers a dominant gain-of-function effect because lungthe p53M/ mice developed more tumors and a different
spectrum of tumors compared to p53/ mice. More- carcinomas are rarely observed in p53/ mice. How-
ever, most p53/ mice die before six months of age.over, p53M/mice more accurately recapitulate the phe-
notype of LFS patients in that they develop a broad Were null mice to avoid other tumors for 18 months,
perhaps they too would be predisposed to lung adeno-spectrum of tumors, including a variety of carcinomas,
soft tissue and bone sarcomas, leukemias, and even a carcinoma. In order to assess this properly, p53 function
would need to be examined specifically in the lung with-glioblastomamultiforme (the most common brain tumor
observed in LFS patients). The most obvious omission out other background tumors. The conditional point mu-
tant p53 mice presented in this work will be useful forfrom this tumor spectrum was breast carcinomas, the
most common tumor in LFS patients. This omission studying the effects of mutant p53 in particular tissues
or at specific developmental stages.could be due to the action of a background modifier not
present in the 129S4/SvJae genetic background. Indeed,
when crossed to the BALB/c background, p53/ mice Mutant p53 Gain of Function
develop mammary carcinomas at high frequency (Kup- This work presents the first clear in vivo evidence for
erwasser et al., 2000). This observation raises the pros- gain-of-function effects by mutant p53. Since the initial
pect that crossing the pointmutant p53mice onto BALB/c descriptions of p53 knockout mice, there have been
or other backgrounds will further refine the accuracy of persistent questions as towhy they do not developmore
these models. carcinomas when p53 is so often mutated in this class
of tumors. As discussed above, one explanation is that
Differences between Contact and Structural background modifiers that promote the development of
Mutant p53 carcinomas in humans may be absent from certain in-
While numerous studies have reported biochemical dif- bred laboratory mouse strains. However, our data sup-
ferences between contact and structural mutant p53 port a model in which epithelial carcinogenesis is en-
proteins (Halevy et al., 1990; Hinds et al., 1990), our work hanced by the production of point mutant p53, rather
represents the first clear evidence of a differential effect than the loss of p53. p53M/mice spontaneously develop
on tumorigenesis in vivo. p53R270H/ mice develop an a variety of carcinomas in addition to thenormal comple-
increased incidence of carcinomas and B cell lympho- ment of tumors previously associated with p53-null mu-
mas compared to p53/ mice. p53R172H/ mice develop tations in mice. Furthermore, mutant p53 accumulation
an increased incidence of metastatic osteosarcomas occurred commonly in carcinomas from p53M/mice but
(and a trend toward more carcinomas). Among LFS pa- not in lymphoblastic lymphomas. It is also notable that
tients, few connections between particular mutations two of the tumors commonly found in p53-null mice,
and phenotypes have been described. lymphoblastic lymphomas and teratocarcinomas, rarely
Themolecular basis for thedifference in tumor spectra harbor p53 mutations in humans. Rather, both tumors
between p53R270H/ and p53R172H/ mice is unclear, but are associated with functional inactivation of p53, such
data derived from primary cells isolated from thesemice as through HDM2 overexpression (Eid et al., 1999; Zhou
uncovered some functional differences between the et al., 1995). Likewise, HDM2 overexpression is found
contact and structural mutant proteins in the presence in over one-third of human sarcomas, the third major
of wild-type p53. For example, p53R270H/ MEFs prolifer- tumor type in p53-null mice (Cordon-Cardo et al., 1994;
ated only modestly faster than p53/ MEFs while Oliner et al., 1992). These correlations further support
p53R172H/ MEFs doubled nearly as fast as p53/ cells. the idea that p53 inactivation (combined with alterations
In contrast, neither mutant interfered with the induction in other genes) is sufficient for tumorigenic progression
of G1 arrest after DNA damage in MEFs. in a subset of tissues.
In concurrent work, Guillermina Lozano and col-
leagues have also generated a p53R172H mouse throughDominant Effects of Mutant p53
In addition to effects on the basal proliferation rate in similar techniques (Lang et. al, 2004 [this issue of Cell]).
Although they observed a similar spontaneous tumorMEFs, mutant p53 exhibited dominant effects on radia-
tion-induced apoptosis in thymocytes; p53M/ thymo- phenotype in heterozygous mutant p53 mice, they did
not observe an increase in carcinomas or other tumorscytes had levels of apoptosis intermediate to p53/ and
p53/ thymocytes. The simplest explanation for this in p53R172H/R172H mice. This may be due to differences
in strain background: Lozano’s mice were enriched foreffect is that both p53R270H and p53R172H interfere with the
ability of wild-type p53 to transactivate apoptotic target C57Bl/6 while our mice were enriched for 129S4/SvJae.
The data presented here provide strong support forgenes through a dominant-negative mechanism. How-
ever, these experiments do not rule out dominant gain- the protumorigenic effects of point mutant p53. At the
molecular level, several mechanisms have been pro-of-function effects by mutant p53. That is, the decrease
in radiation-induced apoptosis in p53M/ thymocytes posed to explain mutant p53 gain-of-function effects
(reviewed in Cadwell and Zambetti [2001]). For example,may be due to interference with the function of wild-
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were collected in trypsin, quenched with medium, and washed inmutant p53 may be able to transactivate novel target
PBS; FACS analysis was performed as described (Kastan et al.,genes such asmdr, BAG-1, or c-myc. Alternatively, mu-
1992). Tumor-derived cell lines were grown on plastic in DME/tantp53mayparticipate in novel protein-protein interac-
HEPES  10% FBS  Pen/Strep.
tions. Perhaps the most well-characterized interaction
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